Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
作者： Garyphallia Poulakou , Helen Giamarellou
DOI: 10.1517/13543784.17.5.749
关键词: Imipenem 、 Drug resistance 、 Microbiology 、 Antibiotics 、 Acinetobacter baumannii 、 Medicine 、 Doripenem 、 Meropenem 、 Carbapenem 、 Pseudomonas aeruginosa
摘要: Background: Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. Objective: This drug evaluation focuses on position of doripenem, a novel forthcoming carbapenem. Mechanisms resistance with anti-Gram-negative activity also briefly reviewed. Methods: Literature search was performed for carbapenems, antibiotics, metallo-β-lactamase inhibitors, pathogens, antipseudomonal antibiotics epidemiology. Results: Doripenem possesses broad spectrum similar to that meropenem, while retaining imipenem Gram-positive pathogens. Against P. aeruginosa, doripenem exhibits rapid bactericidal 2 – 4-fold lower MIC values, compared mero...
informapharmascience.com参考文章(99)
David M Livermore, The impact of carbapenemases on antimicrobial development and therapy. Current opinion in investigational drugs. ,vol. 3, pp. 218- 224 ,(2002)
B GUIGNARD, J ENTENZA, P MOREILLON, β-lactams against methicillin-resistant Staphylococcus aureus Current Opinion in Pharmacology. ,vol. 5, pp. 479- 489 ,(2005) , 10.1016/J.COPH.2005.06.002
Evangelos J Giamarellos-Bourboulis, Anastasia Antonopoulou, Maria Raftogiannis, Pantelis Koutoukas, Thomas Tsaganos, Vassiliki Tziortzioti, Charalambos Panagou, Theodoros Adamis, Helen Giamarellou, Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infectious Diseases. ,vol. 6, pp. 31- 31 ,(2006) , 10.1186/1471-2334-6-31
T.R. Fritsche, M.G. Stilwell, R.N. Jones, Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003) Clinical Microbiology and Infection. ,vol. 11, pp. 974- 984 ,(2005) , 10.1111/J.1469-0691.2005.01271.X
Masakatsu Tsuji, Yoshikazu Ishii, Akira Ohno, Shuichi Miyazaki, Keizo Yamaguchi, In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 94- 99 ,(1998) , 10.1128/AAC.42.1.94
G. B. Calandra, C. Wang, M. Aziz, K. R. Brown, The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients Journal of Antimicrobial Chemotherapy. ,vol. 18, pp. 193- 202 ,(1986) , 10.1093/JAC/18.SUPPLEMENT_E.193
J. R. Edwards, Meropenem: a microbiological overview Journal of Antimicrobial Chemotherapy. ,vol. 36, pp. 1- 17 ,(1995) , 10.1093/JAC/36.SUPPL_A.1
YASUYOSHI Iso, TADASHI IRIE, YUTAKA NISHINO, KIYOSHI MOTOKAWA, YASUHIRO NISHITANI, A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems. The Journal of Antibiotics. ,vol. 49, pp. 199- 209 ,(1996) , 10.7164/ANTIBIOTICS.49.199
Ronald N. Jones, Helio S. Sader, Thomas R. Fritsche, Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms Diagnostic Microbiology and Infectious Disease. ,vol. 52, pp. 71- 74 ,(2005) , 10.1016/J.DIAGMICROBIO.2004.12.008
S. Ragnar Norrby, Kathleen M. Gildo, Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scandinavian Journal of Infectious Diseases. ,vol. 31, pp. 3- 10 ,(1999) , 10.1080/00365549950161808